Literature DB >> 12523871

Predictors of noncompliance in patients with schizophrenia.

Diana O Perkins1.   

Abstract

BACKGROUND: Around 50% of patients with schizophrenia do not fully comply with treatment, and noncompliance is linked to relapse, rehospitalization, poor outcome, and high economic costs. The health belief model views noncompliance as a decision made by the patient, arrived at after weighing the perceived risks and benefits of treatment. DATA SOURCES: A MEDLINE search for the years 1980-2002 using combinations of the keywords schizophrenia, compliance, adherence, antipsychotics, tolerability, and side effects was used to identify articles investigating the factors influencing compliance in schizophrenia.
RESULTS: Many factors influence compliance, including those that affect patients' beliefs about their illness and the benefits of treatment (e.g., insight into illness, belief that medication can ameliorate symptoms), perceived costs of treatment (e.g., medication side effects), and barriers to treatment (e.g., ease of access to treatment, degree of family or social support). Medication side effects that are distressing to patients and linked to noncompliance include extrapyramidal side effects, neuroleptic dysphoria, akathisia, sexual dysfunction, and weight gain. Compliance can be improved by cognitive-behavioral therapies, such as compliance therapy, and other psychosocial interventions associated with improved social functioning and a lower risk of rehospitalization. Treatment adherence may also be improved by use of atypical antipsychotics with few perceived side effects.
CONCLUSION: By considering the factors leading to noncompliance and adopting a comprehensive strategy for improving compliance, encompassing psychosocial intervention and optimum choice of medication, the management of schizophrenia could be greatly improved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12523871     DOI: 10.4088/jcp.v63n1206

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  93 in total

1.  Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection.

Authors:  Wen-Sy Tsai; Pao-Shiu Hsieh; Chien-Yuh Yeh; Jy-Ming Chiang; Reiping Tang; Jinn-Shiun Chen; Chung Rong Changchien; Jeng Yi Wang
Journal:  Int J Clin Oncol       Date:  2012-01-20       Impact factor: 3.402

2.  A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Authors:  Howard Zwibel; Gabriel Pardo; Shelly Smith; Douglas Denney; Merrikay Oleen-Burkey
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

3.  Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.

Authors:  Meike Kasten; Norbert Brüggemann; Inke R König; Katja Doerry; Susanne Steinlechner; Liv Wenzel; Katja Lohmann; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

Review 4.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 5.  Guidelines for clinical treatment of early course schizophrenia.

Authors:  Matcheri S Keshavan; Mary Roberts; Daniela Wittmann
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

6.  Use of depot antipsychotic medications for medication nonadherence in schizophrenia.

Authors:  Joyce C West; Steven C Marcus; Joshua Wilk; Lisa M Countis; Darrel A Regier; Mark Olfson
Journal:  Schizophr Bull       Date:  2007-12-18       Impact factor: 9.306

7.  [Causes of non-compliance of patients who attend a community pharmacy in Granada].

Authors:  Mercedes Bueno Gómez; María Dolores Barrionuevo Sancho; Narjis Fikri Benbrahim; Emilio García-Jiménez
Journal:  Aten Primaria       Date:  2008-02       Impact factor: 1.137

8.  Medication adherence among older adults with schizophrenia.

Authors:  Heather C Leutwyler; Patrick J Fox; Margaret Wallhagen
Journal:  J Gerontol Nurs       Date:  2013-01-18       Impact factor: 1.254

9.  Baseline patient characteristics and mortality associated with longitudinal intervention compliance.

Authors:  Julia Y Lin; Thomas R Ten Have; Hillary R Bogner; Michael R Elliott
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

10.  Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Authors:  Celine M Laffont; Roberto Gomeni; Bo Zheng; Christian Heidbreder; Paul J Fudala; Azmi F Nasser
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.